Snapshot · Stryker Corporation (SYK)

Data as of 2026-10-19T08:14:28.114Z

Fundamentals check

Market cap

$113.0B

P/E (TTM)

30.3

Gross margin

65.2%

Net margin

14.4%

ROE

16.4%

R&D / revenue

6.4%

Dividend yield

1.2%

FCF yield

4.2%

Latest dividend: $0.88/share (ex-date 2026-09-30, quarterly)

Summary

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

How it makes money

Revenue mix, latest fiscal year

• MedSurg62.3%
• Orthopaedics37.7%

Recent Events

• 2026-10-15T00:00:00.000Zpositive

  Price move: SYK rose 4.1%

  SYK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-14T09:03:00.000Zpositive

  Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal

  可能与公司产品创新相关，恰逢新一代手术设备推出，对SYK的市场竞争力有潜在积极影响。

  Source: prnewswire.com

• 2026-10-13T03:11:59.000Zpositive

  Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story

  可能与季度业绩回升及组合扩张有关，恰逢财务表现改善，或有助于投资者对SYK的前景做出积极判断。

  Source: seekingalpha.com

• 2026-10-06T09:02:46.000Zpositive

  Stryker (NYSE: SYK) lines up 2027 CEO handoff as Lobo becomes Executive Chair

  可能与公司治理与接班计划相关，恰逢长期管理层变动，或对股价产生中长期影响。

  Source: defenseworld.net

• 2026-10-05T07:30:00.000Zpositive

  Stryker: This Dividend Aristocrat Is Finally Cheap Again

  可能与估值出现改善相关，恰逢价格回落后估值具有吸引力，或对投资者情绪有正向作用。

  Source: seekingalpha.com

• 2026-09-08T00:00:00.000Znegative

  Price move: SYK fell 8.8%

  SYK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-20T00:00:00.000Znegative

  Price move: SYK fell 3.6%

  SYK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-31T00:00:00.000Znegative

  Price move: SYK fell 6.4%

  SYK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $357.83 from 12 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-21SellCrotty Dylan Bram(officer: Group President)441 shares
• 2026-08-19SellSTRYKER RONDA E(director)805 shares
• 2026-08-19SellSTRYKER RONDA E(director)3,852 shares
• 2026-08-19SellSTRYKER RONDA E(director)3,274 shares
• 2026-08-19SellSTRYKER RONDA E(director)16,612 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。